Authors
Latest:
Long-Acting Injectable HIV Therapy: Addressing Adherence ChallengesElizabeth Hastie, MD discussed the LATITUDE trial results, highlighting the need for wider access to this treatment, especially for those not virally suppressed, and could help shape future healthcare guidelines.
Latest:
Precision Dosing of To-Marrow: Linezolid Therapeutic Drug MonitoringEmerging literature suggests therapeutic drug monitoring for this antimicrobial to minimize the risk for linezolid-associated toxicities while maintaining efficacy in select populations.
Latest:
Bugworks' Antibiotic BWC0977 Targets Resistant PathogensBala Subramanian, PhD, highlights how the novel antibiotic BWC0977, with its dual intravenous and oral formulation, is poised to transform the fight against antimicrobial resistance.
Latest:
Will We Ever See Oral Carbapenems for ESBL Urinary Tract Infections?Recent issues surrounding the ADAPT-PO and SURE-2 trials place the spotlight on the difficulties developing oral carbapenem-based antibiotics and case their future into doubt.
Latest:
From Single-Use to Multi-Use: A Brief Review of N95 Respirator Decontamination StrategiesThis indispensable personal protective equipment did come up in short supply and reuse strategies has become a topic of great interest and research.
Latest:
Unveiling Gender Disparities in Lyme Disease: A Critical Analysis of Persistent IllnessVery few Lyme disease studies consider sex- and gender-based differences. Is this flawing the research?
Latest:
PrEP State of the Union: Adherence, Access, Uptake IssuesAlthough this form of prophylaxis is highly protective, there are situations in which breakthrough infections occur.
Latest:
Antibiotic De-Escalation: Is This the Right Outcome Measure?The proposed clinical benefits of de-escalation has contributed to its lukewarm adoption in some settings. This article looks at the challenges in measuring the impact of de-escalation, and the ongoing search for more meaningful metrics to evaluate the success of antimicrobial stewardship (AMS) programs.
Latest:
Ceftriaxone as Definitive OPAT for MSSA Bloodstream InfectionsA cautious approach for now is warranted as well as a need for a randomized clinical trial.
Latest:
Employee Health After the COVID-19 Pandemic: Stronger Than YesterdayFor providers on the front lines, lessons learned can help inform strategies to enhance the protection of their health going forward.
Latest:
When Will the Measles Outbreak End?Paul Offit, MD, offers a glimpse of when the outbreak might end as well as where we are with herd immunity, the MMR vaccine’s efficacy, and insights on breakthrough cases.
Latest:
Where Do We Draw the Line? Duration of Antibiotic Therapy Varies for Bloodstream InfectionsWith potential delays in treatment, bloodstream infections can be concerning for clinicians. Here is a review of the literature that offer guidance for treatment.
Latest:
Strengths and Limitations of T2Candida Implementation From an Antimicrobial Stewardship PerspectiveThis novel, rapid diagnostic assay uses polymerase chain reaction and magnetic resonance to identify the 5 most common Candida species.
Latest:
ASM Microbe Conference: "Great Migration of Microbiologists"American Society for Microbiology (ASM) CEO Stefano Bertuzzi, PhD, MPH, talks about ASM's comprehensive scientific program, the networking opportunities at the meeting, and the unique format ASM plans to roll out for the 2026 conference.
Latest:
Considering a Beta Lactam as Adjunctive Therapy for Staphylococcus aureus Early in TreatmentThis bacteremia can present heterogeneously and be difficult to contain, especially in an older patient population. Daniel B. Chastain, PharmD, BCIDP, AAHIVP, FIDSA, reviews the data of this class of therapies and how it may be clinically beneficial in combination with other antimicrobials.
Latest:
HIV Education and Advocacy in an Age of UncertaintyJoseph Cherabie MD, MSc, explains the importance of how these 2 components go hand-in-hand, and what it means to continue forward in spite of being in an unpredictable time.
Latest:
What Is a Better Treatment Approach for Immunocompromised Hosts With Clostridioides difficile Infection?Here is a review of the effectiveness of fidaxomicin vs vancomycin for CDI treatment in populations with immunocompromised conditions.
Latest:
Survey Highlights Critical Role of Pharmacists in HCV ManagementSurvey data show pharmacists are integral to HCV screening and treatment across healthcare settings, highlighting their contributions to HCV elimination efforts.
Latest:
mRNA Capping: A Component That Protects the COVID-19 Vaccine and Lends to its EffectivenessKate Broderick, PhD, molecular geneticist, discusses the mRNA capping technology and how it helps create stability to mRNA molecules within vaccines and guides them to cells.
Latest:
Recent Research Indicates That We're Falling Short on HBV Elimination TargetsOrganizations look at an agent-based model to assess the impact of vaccination, screening, and treatment on incidence and prevalence of HBV in Ontario, Canada.
Latest:
Safety and Immunogenicity Results For Mpox Vaccine MVA-BN in Adolescents Amid Rising ConcernsBuddy Creech, MD, MPH, assures that the interim findings of the study indicate adolescents produced a stronger immune response compared to adults, with minimal adverse effects.
Latest:
The Variety of Variants in COVID-19The evolution of the major variants, including the delta mutation.
Latest:
CRAB-By No More?Understanding the potential and limitations of new Acinetobacter baumannii active therapies.
Latest:
Ordering With ForesightCan duration of therapy requirements at the time of antibiotic order entry decrease antibiotic use?
Latest:
Practice Pearls for Treatment of Respiratory InfectionsTina Tan, MD; Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP; Priya Nori, MD; Jacinda Abdul-Mutakabbir, PharmD; and Kevin Michael Reiter, MD, PA, provide key takeaways from the discussion on the treatment of respiratory viral infections.
Latest:
What is Driving the Global Expansion of Lyme Disease?Climate-driven changes and other drivers of the expanding geographic range of Ixodes ticks and Lyme disease are explored.
Latest:
HIV CRISPR Therapy Fast-Tracked by the FDAThe phase 1/2 trial evaluating EBT-101 dosed its first patient in September 2022.
Latest:
Operation Warp Speed: Bringing Out the Best in America’s Ability to InnovateMatthew Hepburn, MD, offers some insights on his time as vaccine development lead for Operation Warp Speed and the ability to develop a COVID-19 vaccine within a year.
Latest:
The US Will Transition to Trivalent Vaccines for Next Year's Influenza SeasonSince changes in vaccine composition can sometimes lead to confusion or misinformation, effective communication is crucial to promote vaccine uptake.
